HomeProductsBioactive CompoundsCell CycleChkPrexasertib
Chemical structure of CAS 1234015-52-1

Prexasertib

CAS No.1234015-52-1
MDL No.MFCD25977016
MFC18H19N7O2
MW365.40
InChI KeyDOTGPNHGTYJDEP-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1234015-52-1
Product NamePrexasertib

Biological Targets

CHEK1·CHEK2

Associated Conditions

neoplasm·brain cancer·metastasis·chronic myelomonocytic leukemia·cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Coptisine-mediated downregulation of E2F7 induces G2/M phase arrest in hepatocellular carcinoma cells through inhibition of E2F4/NFYA/NFYB transcription factors.

Chemico-biological interactions • Vol. 397 • 2024
PMID: 38795876DOI: 10.1016/j.cbi.2024.111063

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Cell biology and toxicology • Vol. 39, Issue 3 • 2023
PMID: 34519926PMC: PMC10406704DOI: 10.1007/s10565-021-09640-x

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 23, Issue 15 • 2017
PMID: 28270495DOI: 10.1158/1078-0432.CCR-16-2876

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.

Molecular cancer therapeutics • Vol. 14, Issue 9 • 2015
PMID: 26141948DOI: 10.1158/1535-7163.MCT-14-1037

Documentation

Similar Products